Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF)

The QualityStocks Daily Newsletter would like to spotlight Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF).

This article has been disseminated on behalf of Powermax Minerals Inc. and may include paid advertising.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF) (FSE: T23) has completed its 2025 field exploration program at the Atikokan rare earth elements property in northwestern Ontario, encompassing geological mapping, prospecting, radiometric surveys and systematic geochemical sampling across multiple priority target areas. The program collected 426 samples, including soil, sediment and rock samples with QA/QC controls, and delineated three principal lithological domains, with mapping identifying granitic and pegmatitic units considered prospective for REE mineralization, providing geological context to guide follow-up exploration and target prioritization.

To view the full press release, visit https://ibn.fm/d5l4n

Disseminated on behalf of Powermax Minerals Inc., may include paid advertisements.

Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) is a Canadian mineral exploration company developing a portfolio of rare earth element (“REE”) projects across Tier-1 jurisdictions in Canada and the United States. Focused on discovery, responsible advancement, and alignment with North America’s critical-minerals strategy, the company targets areas with geological potential for REE-bearing pegmatites and granitic systems.

Its exploration model emphasizes modern geophysics, data integration, and systematic de-risking through technical work. By concentrating on projects with clear infrastructure advantages and policy support, Powermax seeks to contribute meaningfully to regional supply-chain independence in critical minerals vital to electrification and advanced manufacturing.

The company’s growing asset base includes four core REE projects, Atikokan, Cameron, Pinard and Ogden Bear Lodge, positioned within highly prospective geological corridors.

Powermax Minerals is headquartered in Toronto, Ontario.

Projects

Atikokan REE Project – Northwestern Ontario

Powermax’s flagship Atikokan Rare Earth Element Project covers 9,416 hectares across three mineral claim blocks (A, B, and C) approximately 35 kilometers northwest of the town of Atikokan in the Thunder Bay Mining District. Located along the White Otter–Dashwa corridor, the project hosts REE-enriched granitic and pegmatitic systems supported by strong radiometric and geochemical signatures.

In 2025, Powermax completed airborne magnetic and gamma-ray spectrometric surveys, geological mapping, and geochemical sampling. An integrated interpretation released in November 2025 outlined a structural–geochemical corridor of REE enrichment, with Total Rare Earth Element (TREE) values from 254 ppm to 1,947 ppm across Blocks B and C. The company is currently advancing surface validation and target ranking for follow-up work.

Cameron REE Project – British Columbia

The Cameron Project, which the company holds an option to acquire, is located about 30 kilometers south of Revelstoke in the Kamloops Mining Division and comprises three contiguous mineral claims totaling 2,984 hectares.

Hosted within the Monashee Group, the property contains NYF-type granitic pegmatites and gneissic units known to carry both light and heavy REEs. Phase 1 exploration, completed under NI 43-101 recommendations, produced TREE values ranging from 17 ppm to 1,943 ppm, with heavy mineral concentrate samples up to 7,561 ppm. These findings confirmed consistent REE enrichment and led to the launch of Phase 2 exploration in October 2025 to expand mapping and refine drill targets.

Ogden Bear Lodge REE Project – Wyoming, USA

Powermax owns a 100% interest in the Ogden Bear Lodge Project, covering 22 lode claims (184 hectares) in Crook County, Wyoming. The property is prospective for high-grade neodymium-praseodymium (Nd/Pr) oxide mineralization and shares a border with Rare Element Resources’ Bear Lodge Critical Rare Earth Project. That neighboring project has received $24.2 million in U.S. Department of Energy support and a non-binding EXIM Bank letter of interest for up to $553 million in debt financing, highlighting the strategic value of this emerging U.S. REE district.

Pinard Rare Earths Project – Northern Ontario

In November 2025, Powermax Minerals announced plans to acquire a 100% interest in the Pinard Rare Earths Project, located roughly 70 kilometers north-northeast of Kapuskasing, Ontario. The property consists of 255 contiguous claims totaling 5,178 hectares within the Pinard Intrusive Rock Complex, an alkaline igneous system characterized by nepheline syenites and peralkaline granites commonly associated with REE-bearing mineralization.

Market Opportunity

Global demand for rare earth elements is projected to triple—from 59,000 tonnes in 2022 to 176,000 tonnes by 2035—driven by rapid electric-vehicle adoption and wind-power expansion, with supply expected to lag by up to 30%. The global REE market, valued at $3.95 billion in 2024, is forecast to reach $6.3 billion by 2030 at a compound annual growth rate of approximately 8.6%, according to Grand View Research.

China currently controls approximately 60% of REE mining and about 90% of processing capacity, prompting North American governments to accelerate domestic development. In 2025, the U.S. Department of Energy announced $1 billion in critical-minerals funding opportunities, while Canada’s C$1.5 billion Critical Minerals Infrastructure Fund supports projects through 2030. Together, this policy support and structural supply deficit highlight Powermax’s positioning within a strategically essential market tied to the clean-energy transition.

Leadership Team

Paul Gorman, CEO & Director, is a resource-based corporate specialist with more than 25 years of experience in junior mining finance, public listings, and corporate development. He is the President and Managing Partner of Riverbank Capital Inc., where he has raised over $150 million for emerging issuers and helped revitalize the North American graphite industry through the founding of Mega Graphite Inc. Gorman has led multiple exploration programs and was instrumental in achieving high-grade lithium discoveries in 2024 for Pan American Energy Corp.

Michael Malana, Director, has more than 20 years of international experience in financial management, reporting, and corporate governance. He has held senior executive roles across natural resources, biotechnology, and manufacturing and holds a Bachelor of Commerce degree from Concordia University in Montreal. Malana is a Chartered Professional Accountant (Certified Management Accountant).

Afzaal Pirzada, M.Sc., P.Geo., Director, is a professional geoscientist with over 30 years of experience in mineral exploration and mining, specializing in gold, lithium, graphite, rare metals, and uranium. He has served as Project Geologist, VP Exploration, Director, and CEO for multiple mining companies, including Adriana Resources and Rock Tech Lithium. Pirzada is a registered Professional Geoscientist with Engineers and Geoscientists British Columbia and has authored numerous NI 43-101 technical reports.

Powermax Minerals Inc. (OTCQB: PWMXF), closed Wednesday's trading session at $1.11, up 1.8442%, on 159,248 volume. The average volume for the last 3 months is 202,130 and the stock's 52-week low/high is $0.6116/$1.45.

Recent News

• Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) - RockBreaks - Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) (FSE: T23) Completes 2025 Exploration Program at Atikokan REE Property
• MiningNewsBreaks - Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Builds Multi-Project Rare Earth Pipeline Across Canada and the US
• NetworkNewsBreaks - Why Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Is 'One to Watch'

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising.

MAX Power Mining (CSE: MAXX) OTC: MAXXF) (FRANKFURT: 89N) has closed a non-brokered private placement for gross proceeds of $5 million (CDN), marking the first large investment by a Vietnam-based company in Saskatchewan and forming part of a strategic partnership with Bitexco affiliate Big Energy. The investment supports accelerated exploration and potential commercial development of natural hydrogen across MAX Power 1.3 million-acre permitted land package in Saskatchewan, positioning the Company to advance discovery efforts within what is emerging as a new primary clean energy sector.

To view the full press release, visit https://ibn.fm/gbTXo

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Wednesday's trading session at $0.419, up 1.9465%, on 74,082 volume. The average volume for the last 3 months is 579,470 and the stock's 52-week low/high is $0.105/$0.711.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - InvestorNewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Closes $5 Million Private Placement With Vietnam-Based Strategic Partner
• AINewsBreaks - MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Featured in MiningNewsWire Editorial on Rising Energy Demand and Natural Hydrogen
• RockBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Appoints Neil McMillan as Chairman of the Board

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Research indicates that the advantages of nanoparticle delivery in pharma are significant

Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform

Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context

In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Wednesday's trading session at $0.09175, up 2.514%, on 25,576 volume. The average volume for the last 3 months is 130,830 and the stock's 52-week low/high is $0.02403/$0.11.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology
• NetworkNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences
• Antisense's Moment: How Rational Design Is Rewriting Drug Development Economics

Xeriant Inc. (OTCQB: XERI)

The QualityStocks Daily Newsletter would like to spotlight Xeriant Inc. (OTCQB: XERI).

Xeriant (OTCQB: XERI) , a technology company focused on the discovery, development and commercialization of advanced and sustainable materials, has engaged IBN to support its corporate communications strategy. Xeriant operates as a strategic holding company with exposure to next-generation aerospace and advanced materials technologies, including its DUREVER(TM) advanced materials program led by NEXBOARD(TM), a patent-pending composite construction panel made from recycled plastic and fiber waste and enhanced with proprietary nanotechnology-based fire retardants, which is being developed as a high-performance alternative to traditional building materials and is undergoing testing and certification.

To view the full press release, visit https://ibn.fm/JoeU0

Xeriant Inc. (OTCQB: XERI) is dedicated to the discovery, development and commercialization of emergent, transformative technologies, focusing on eco-friendly advanced materials with applications across multiple industries.

The company builds its technology portfolio through strategic partnerships, acquisitions, and internal development programs, emphasizing diversification and synergy, and is supported by its innovation platform called Factor X Research Group. Xeriant’s affiliated entities maintain operational focus and expertise while becoming part of a collaborative interdisciplinary innovation hub aimed at enhancing capabilities and accelerating technology development and deployment.

Xeriant’s advanced materials line is marketed under the DUREVER™ brand and includes NEXBOARD™, a patent-pending composite construction panel made from recycled plastic and fiber waste, designed to replace drywall, plywood, OSB, MDF, MgO board and other construction panels.

The company is headquartered in Boca Raton, Florida.

Portfolio

NEXBOARD™

Xeriant’s primary commercial focus is NEXBOARD™, an eco-friendly composite construction panel made from recycled plastic and fiber waste and enhanced with the company’s proprietary nanotechnology-based fire retardant, marketed under the DUREVER™ brand. Internal tests have demonstrated exceptional fire resistance, including a five-minute torch test reaching up to 2,500ºF and an 80-minute high-heat evaluation exceeding 2,000ºF.

The company has completed multiple limited production runs and internal tests to support certification, with accredited agencies documenting materials, processes, and quality controls. Upcoming certification testing includes NFPA 286 and ASTM E84, along with structural and durability testing.

Factor X Research Group

Factor X is Xeriant’s advanced innovation division, established to accelerate high-impact technologies from concept to commercial deployment. Modeled after Lockheed’s Skunk Works™, the group brings together experts across advanced materials, aerospace, artificial intelligence, critical infrastructure, and related disciplines to streamline development and strengthen cross-functional collaboration.

Its expanded mandate includes identifying acquisition opportunities; targeting disruptive technologies in areas such as AI, quantum computing, and data science; and supporting products like NEXBOARD™ as they move through the company’s commercialization pipeline.

Under the leadership of Brig. Gen. (Ret.) Blaine D. Holt, Factor X provides a coordinated environment designed to unify technical teams, reduce development barriers, and advance innovations with near-term market potential.

Market Opportunity

Xeriant operates at the intersection of several rapidly expanding sectors, including advanced aerospace systems, sustainable construction materials, and next-generation industrial technologies. Demand for eco-friendly building materials continues to accelerate, with the green construction market projected to reach $1.8 trillion by 2030, according to a World Economic Forum report, supported by rising global standards for safety, sustainability, and carbon reduction. NEXBOARD also participates in the broader fire-protection materials market, which is projected to grow from $37.69 billion in 2025 to $59.9 billion by 2034, according to Market Research Future, driven by stricter building codes and increasing awareness of fire-resistant alternatives.

Xeriant plans to capitalize on opportunities emerging from green construction, modular homebuilding, advanced composites engineering, nanotechnology, thermal-management innovations, and cross-disciplinary integration for new product development. Each prospective technology undergoes rigorous due diligence, including market forecasting, management evaluation, competitive assessment, and financial analysis, allowing Xeriant to pursue selective, strategically aligned acquisitions and partnerships.

Leadership Team

Keith F. Duffy, Chairman and Chief Executive Officer, has more than 30 years of experience across investment banking, finance, strategic planning, and operations, and has served as a principal in multiple start-ups spanning aviation, software, banking, and biotech. He arranged the merger that created Xeriant, established the company’s partnership with Florida Atlantic University, and previously held roles ranging from securities broker to controller of an aviation FBO. He is a licensed real estate and mortgage professional and holds a B.A. in Business Administration and Mathematics from Rollins College.

Scott M. Duffy, Executive Director of Corporate Operations, has built a career of over 30 years in management, operations, strategic planning, IT, marketing, and distribution, including oversight of a $545 million retail sales division at American Media. He has collaborated on business development efforts for several start-ups, including Xeriant, and has held senior roles supporting large-scale operational and administrative functions. He earned a B.A. in Business Administration and Mathematics from Rollins College.

Pablo Lavigna, Chief Information Officer, has more than 20 years of experience in information technology and software engineering, supporting Xeriant through technology sourcing, internal systems management, and the development of security and software solutions. His background includes directing IT operations for private firms and implementing network security and specialized software tools across multiple industries. He holds Microsoft and CompTIA certifications and graduated magna cum laude from Florida International University with a degree in Information Technology and Business.

Brian Carey, Chief Financial Officer, has spent over 30 years in accounting, tax, financial management, and business development, having founded and operated a long-standing accounting and advisory firm serving start-ups and established companies. His experience includes business planning, financial oversight, and operational support for partner organizations. He holds a Bachelor of Accounting degree from Penn State University.

Brig. Gen. (Ret.) Blaine D. Holt, President of Factor X Research Group, has a distinguished background in multinational operations, aerospace leadership, and technology-driven enterprise, including service as Deputy U.S. Military Representative to NATO and as a command pilot with more than 3,900 flight hours. His experience spans advanced manufacturing, AI-enabled logistics, large-scale aviation turnarounds, and advisory work supporting emerging technologies, strengthening Xeriant’s ability to evaluate and advance high-impact innovations.

Xeriant Inc. (OTCQB: XERI), closed Wednesday's trading session at $0.0145, up 51.0417%, on 2,105,212 volume. The average volume for the last 3 months is 1,091,630 and the stock's 52-week low/high is $0.003735/$0.0295.

Recent News

• Xeriant Inc. (OTCQB: XERI) - InvestorNewsBreaks - Xeriant, Inc. (OTCQB: XERI) Engages IBN to Support Corporate Communications Strategy
• DefenseNewsBreaks - Xeriant, Inc. (OTCQB: XERI) Highlights Advancement of NEXBOARD as Certification Readiness Nears 
• Platforms, Proof, and Momentum

Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF)

Disseminated on behalf of Search Minerals Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF).

Disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising.

Search Minerals (TSX.V: SMY) (OTC: SHCMF) , an exploration and development company, is focused on maximizing critical rare earth element ("CREE") resources in Labrador, Canada. "Founded in 2009, the company has invested heavily in the acquisition, exploration, and development of high-value REE assets, with the primary aim of creating a source of minerals needed for clean energy, technology, and defense," reads a recent article. "Port Hope Simpson–St. Lewis CREE District, a core portfolio for the company located in the southeastern Labrador area, currently hosts the Deep Fox and Foxtrot Projects, in addition to over 20 new prospects discovered by Search Minerals. In addition to this, there is the Red Wine CREE District located in central Labrador, which is home to several prospects such as Merlot, Two Tom, and Mann #1. These districts form an integral part of the process towards Canada's critical mineral independence."

To view the full article, visit https://ibn.fm/bnzrd

Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) is a mineral exploration and development company focused on advancing critical rare earth element (“CREE”) resources in Labrador, Canada. Since its establishment, the company has concentrated on systematic exploration supported by detailed geological work, extensive sampling, and disciplined technical evaluation across its landholdings.

The company operates with an emphasis on transparency, field-based science, and engagement with local communities and partners, including the NunatuKavut Community Council and municipal leaders in the surrounding region. Its technical programs and community initiatives reflect an ongoing commitment to responsible exploration and long-term regional collaboration.

Through continued exploration, environmental review, and stakeholder dialogue, Search Minerals is working to advance its rare earth assets toward future development within a supportive and mining-friendly jurisdiction.

The company is headquartered in St. Lewis, Newfoundland and Labrador.

Projects

Port Hope Simpson – St. Lewis CREE District

Deep Fox

Deep Fox has emerged as Search Minerals’ leading resource, supported by extensive drilling, channel sampling, and feasibility-related technical work. Located 2 km northeast of St. Lewis with direct road and tidewater access, the project has been defined through 137 drill holes (25,741 m), 44 channels (1,096 m), geophysical surveys, and nearly 15,500 assays. Mineralization is hosted in steeply dipping pantellerite and extends up to 42 m thick across an approximate 400 m strike length. Phase 4 programs confirmed strong Nd–Pr–Dy–Tb values from surface to at least 200 m depth and expanded the zone both east and west. These results will support an updated mineral resource estimate and advance Deep Fox toward feasibility-level assessment.

Foxtrot

Foxtrot, the company’s first major discovery, lies 10 km west of St. Lewis and has been advanced through extensive work programs including 1,484 channel samples, 72 drill holes, mapping, and geophysics. The mineralized zone is well understood from surface to depth, with consistent alignment between channel and drill core assays. Foxtrot hosts an indicated resource of 10.04 million tonnes and an inferred resource of 3.00 million tonnes (December 2021), and forms part of the combined 2022 mineral resource estimate alongside Deep Fox.

Fox Meadow

Fox Meadow is a large-scale, high-priority exploration target located 11 km west of Port Hope Simpson. The mineralized zone is up to 175 m wide with a current strike length of 680 m, supported by magnetic anomalies extending over 1 km. Channel results indicate more moderate grades than Deep Fox and Foxtrot, but the scale and notably low uranium and thorium values present compelling advantages. Mineralization is structurally complex and hosted in trachytic pantellerites enriched in allanite, fergusonite, and zircon. A 2,000 m drill campaign and additional channel sampling were completed in late 2022, with results pending.

Other Prospects Along the Belt

Search Minerals controls multiple additional discoveries across its 64 km Fox Harbour volcanic belt:

• Silver Fox hosts high-grade zirconium, hafnium, and rare earths, with channel samples showing Zr concentrations surpassing 25,000 ppm.
• Awesome Fox contains strong Nd–Pr–Dy–Tb values across several wide channel intervals.
• Foxy Lady, Fox Run, and Krazy Fox exhibit CREE-enriched mineralization within the same peralkaline stratigraphy that hosts Deep Fox and Foxtrot.

These prospects collectively reinforce the district’s potential to support multiple future development opportunities beyond the flagship assets.

Red Wine CREE District

Search Minerals also controls 17 licenses (427 claims) in central Labrador within the Red Wine CREE District, prospective for both light and heavy rare earth elements as well as niobium and beryllium. Key prospects include Two Tom Lake, Mann #1, Merlot, Dory Pond, Cabernet, and Barbera. Channel assays released in 2025 confirmed significant concentrations of Nb, Be, Nd, Pr, Dy, and Tb across multiple targets. This district remains at an earlier stage but represents long-term upside, with ongoing prospecting, mapping, and additional channel sampling planned to prepare for future drilling.

Market Opportunity

Global demand for rare earth elements is projected to triple from 59,000 tonnes in 2022 to 176,000 tonnes by 2035 as electric-vehicle adoption accelerates and wind-power capacity expands. The global REE market, valued at $3.95 billion in 2024, is expected to reach $6.3 billion by 2030 at a compound annual growth rate of approximately 8.6%, according to Grand View Research. With supply projected to lag demand by as much as 30%, the outlook points to a sustained structural deficit in key magnet materials.

China currently controls roughly 60% of global REE mining and about 90% of processing capacity, prompting major efforts in North America to strengthen domestic supply chains. In 2025, the U.S. Department of Energy announced $1 billion in critical-minerals funding programs, while Canada’s C$1.5 billion Critical Minerals Infrastructure Fund will support project development through 2030. These initiatives underscore the importance of strengthening domestic rare earth supply chains.

In this environment of rising demand, constrained supply, and coordinated policy support, Search Minerals’ district-scale assets position the company within one of the most strategically vital segments of the clean-energy transition.

Leadership Team

Joseph Lanzon, Chief Executive Officer and Director, brings extensive experience in government relations, strategic communications, and high-level advocacy across regulatory, legislative, and capital markets environments. His background includes promoting shareholder interests at the Toronto Stock Exchange and navigating complex policy landscapes, with a strong foundation in strategic messaging, negotiation, and relationship building.

Jason Macintosh, Chief Financial Officer, brings more than 25 years of comprehensive finance leadership experience. He previously served as CFO and Corporate Secretary for STLLR Gold Inc., where he oversaw accounting and finance operations, established financial controls, and aligned financial strategy with the company’s broader growth and exploration objectives.

Dr. Randy Miller, Vice President, Exploration, holds a Ph.D. in Geology from the University of Toronto and is a registered Professional Geoscientist in Newfoundland and Labrador. He brings extensive rare earth element experience, including work on the Strange Lake deposit and 12 years as the province’s Rare Earth Element and Rare Metal Specialist. His research across Labrador and Newfoundland underpins Search’s exploration model, and he has been with the company since 2009.

Ed Moriarity, Vice President, Environment and External Relations, brings over 25 years of experience across private industry, government, and the non-profit sector. He previously served as Executive Director of Mining Industry NL and as a Director of Communications with the Government of Newfoundland and Labrador, and now leads Search’s environmental engagement and partnership work with the NunatuKavut Community Council. He holds a BA from Memorial University and a Postgraduate Diploma in Business Administration from the University of Roehampton-London.

Search Minerals Inc. (OTC: SHCMF), closed Wednesday's trading session at $0.32054, even for the day. The average volume for the last 3 months is 24,320 and the stock's 52-week low/high is $0.069/$0.6083.

Recent News

• Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) - InvestorNewsBreaks - Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) Advances Canada's Critical Rare Earth Strategy in Labrador
• Where Geology Creates Advantage: Inside Search Minerals Inc.'s (TSX.V: SMY) (OTC: SHCMF) Development Across Labrador's Rare Earth Districts
• Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) Is 'One to Watch'

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Artificial intelligence is quickly becoming part of everyday life, and health care is no exception. Under a major bill pushed by U.S. President Donald Trump, states are now being encouraged to adopt more AI technology in hospitals in exchange for federal funding. Supporters say this could modernize health care, especially in rural areas. However, many experts are urging caution, warning that AI should support care, not replace it or become a shortcut for cutting costs. The bill includes a program known as the Rural Health Transformation Fund. This fund sets aside $50 billion over five years for states that meet certain conditions. One of those conditions is the use of technology-driven health care solutions such as artificial intelligence, robotics, and remote patient monitoring. The goal is to improve care in rural hospitals, which often struggle with staff shortages, limited resources, and outdated systems. There are also serious concerns about safety, regulation, and privacy. While the U.S. Food and Drug Administration regulates AI tools used for diagnoses, many systems that handle patient data, such as transcription tools, face little oversight. This raises questions about accuracy, accountability, and patient protection. Increased use of AI also brings higher risks of data breaches and cyberattacks, especially if hospitals lack strong security systems. Experts stress that AI should not be treated as a cheap fix. For it to work safely, hospitals must invest in staff training, cybersecurity, and clear rules. Without these safeguards, AI could create more problems than it solves. Used wisely, it may help health care. Used carelessly, it could deepen existing cracks in the system. On a positive note, the steps that the federal government is taking to incorporate AI into health care show that governments are willing to adopt new technologies that have utility within their systems. Entities like D-Wave Quantum Inc. (NYSE: QBTS) that focus on developing cutting-edge technologies can therefore be assured that there may be no shortage of market for their solutions once they are appropriately designed and marketed. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $23.8, off by 6.7398%, on 29,361,416 volume. The average volume for the last 3 months is 32,334,591 and the stock's 52-week low/high is $3.74/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Experts Call for Caution as Trump Pushes for AI in Health Care
• Trump Signs Executive Order Blocking State-Level AI Laws
• US Navy, Palantir Partner to Build AI Submarine

Forward Industries Inc. (NASDAQ: FWDI)

The QualityStocks Daily Newsletter would like to spotlight Forward Industries Inc. (NASDAQ: FWDI).

Earlier this year, Forward Industries pivoted toward digital asset management, transforming into the world's largest Solana-based DAT.

The Oak Ridge report observes a notable expansion in institutional activity even amid the downturn in the crypto market.

The report highlights the company's rapid expansion of its digital infrastructure.

Forward Industries (NASDAQ: FWDI) is the focus of a new analyst report from Oak Ridge Financial, which reiterates a Buy rating and establishes a $10 price target. The report highlights the company's ongoing transformation into the world's largest Solana-based Digital Asset Treasury ("DAT") and evaluates why analysts believe the company may be positioned for long-term value creation.

Forward Industries Inc. (NASDAQ: FWDI) is building and managing a large-scale Solana (SOL) treasury, backed by some of the most influential investors in the digital asset space. The company’s strategy centers on long-term shareholder value through active participation in the Solana ecosystem, which it views as uniquely positioned to underpin future global capital markets due to its high throughput, deep economic activity, and growing developer adoption.

Through this shift, Forward Industries aims to create value by accumulating SOL and strategically deploying assets through on-chain opportunities including staking, lending, and participation in decentralized finance (DeFi). Forward also became the first U.S.-listed company to bring its common stock onto the Solana blockchain, reinforcing its focus on digital-native capital markets.

Forward Industries is headquartered in New York.

Solana Treasury Operations

In September 2025, Forward Industries closed a $1.65 billion private investment in public equity (PIPE) led by Multicoin Capital, Galaxy Digital, and Jump Crypto. The PIPE proceeds were deployed to acquire over 6.8 million SOL at an average price of $232 per token, with a portion executed on-chain via DFlow, a decentralized exchange aggregator built exclusively for Solana trading applications. The company has since staked the entirety of its treasury, actively generating yield through native Solana infrastructure and DeFi applications.

Forward’s strategy is centered on growing SOL per share, leveraging a range of tools including at-the-market (ATM) equity offerings and potential preferred equity issuance. The company is also targeting acquisitions and strategic partnerships within the Solana ecosystem to accelerate treasury yield and ecosystem alignment. As part of its infrastructure expansion, Forward tokenized its FORD shares on the Solana blockchain in collaboration with Superstate and plans to acquire an equity interest in the platform. The tokenized shares are expected to enable 24/7 trading, real-time settlement, and eligibility for use as DeFi collateral.

This shift was supported by the company’s board and executive team, whose composition reflects deep alignment with the Solana ecosystem — including leadership from Multicoin Capital and board observers from Galaxy and Jump Crypto. The company’s stated objective is to establish itself as the leading institutional participant in the Solana ecosystem, uniquely positioned to capture both economic yield and strategic exposure to one of the fastest-growing blockchain networks in the world.

Market Opportunity

Solana has emerged as the most performant blockchain in the digital asset space, processing over 8.9 billion transactions in Q2 2025 and sustaining approximately $3 billion in daily decentralized exchange (DEX) trading volume. Year to date, Solana applications have generated over $4 billion in fees and more than $1 billion in real economic value (REV), a proxy for free cash flow generated by the network.

DeFi participation, stablecoin usage, and developer activity have all grown substantially, with over $1.5 trillion in swap volume recorded through 2025. SOL staking yields have averaged over 8%, comprised of both inflationary rewards and organic yield from network activity. With 17 pending ETF applications and major institutions like BlackRock, Visa, PayPal, and HSBC integrating Solana, Forward Industries is positioned to benefit from a rising tide of institutional adoption, tokenization of real-world assets, and increased demand for high-performance blockchain infrastructure.

Leadership Team

Kyle Samani, Chairman of Forward Industries, is the co-founder and Managing Partner of Multicoin Capital, an early Solana backer and one of the largest holders of SOL. Samani contributed $25 million to the PIPE and is a key strategic leader behind Forward’s treasury roadmap.

Mike Pruitt, Interim CEO of Forward Industries, joined the board in February 2025 and was appointed Interim CEO in May. He is the founder of Avenel Financial Group and previously served as CEO of Chanticleer Holdings, bringing decades of public company leadership and capital markets experience.

Kathleen Weisberg, Chief Financial Officer of Forward Industries, was appointed CFO in July 2023 after serving as Corporate Controller since 2020. Weisberg is a CPA with prior roles at WW International, Symbol Technologies, and Ernst & Young.

Forward Industries Inc. (NASDAQ: FWDI), closed Wednesday's trading session at $6.95, off by 2.7972%, on 1,322,023 volume. The average volume for the last 3 months is 849,139 and the stock's 52-week low/high is $3.32/$46.

Recent News

• Forward Industries Inc. (NASDAQ: FWDI) - Forward Industries Inc. (NASDAQ: FWDI) Gains Buy Rating as Solana-Focused Treasury Strategy Strengthens Outlook
• InvestorNewsBreaks - Forward Industries, Inc. (NASDAQ: FWDI) Reports Fiscal 2025 Results Reflecting Early Momentum in Solana Treasury Strategy
• MissionIRNewsBreaks - Forward Industries Inc. (NASDAQ: FWDI) Positions to Focus on SOL Strategy

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under which John Climaco has stepped down as chief executive officer and Rami Levin, MBA, has been appointed president and chief executive officer, effective Jan. 1, 2026. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases, with a track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds, positioning CNS to advance its pipeline and next phase of development.

To view the full press release, visit https://ibn.fm/FBByV

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $6.917, off by 6.4005%, on 75,951 volume. The average volume for the last 3 months is 12,757 and the stock's 52-week low/high is $4.93/$114.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - MissionIRNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer
• Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment
• Optimal Treatment Timing Could Boost Cancer Therapy Efficacy

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) , a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. "The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam's growing influence in the next generation of cardiac monitoring technology," reads the article. "HeartBeam's ranking underscores the rapid maturation of the company's proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain cardiologist-level ECG data from compact devices that can be used by patients or clinicians far from traditional hospital settings. In doing so, HeartBeam is addressing one of modern medicine's most persistent challenges: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. The company is cleared for arrhythmia today, and ischemia is a future goal."

To view the full article, visit https://ibn.fm/3ADRP

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Wednesday's trading session at $3.07, off by 10.7558%, on 36,223,270 volume. The average volume for the last 3 months is 29,644,580 and the stock's 52-week low/high is $0.54/$4.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - AINewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation
• InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software

Safe and Green Holdings Corp. (NASDAQ: SGBX)

The QualityStocks Daily Newsletter would like to spotlight Safe and Green Holdings Corp. (NASDAQ: SGBX).

Safe and Green Holdings (NASDAQ: SGBX) , a diversified holding company, is set to close 2025 with a Dec. 29 shareholder meeting centered on defining the company's next phase in the U.S. energy market. "The meeting is expected to be a significant one for the Texas-based company. Stockholders will vote on the approval enabling the former shareholders of New Asia Holdings Corp. to convert their non-voting preferred shares into common shares, a move representing the final step in integrating Olenox Corp. and Machfu, Inc. into Safe & Green's corporate structure," reads a recent article. "CEO Michael McLaren said the completion of the merger would formalize the company's shift from its former modular construction identity into a fully integrated energy company. ‘This final task in the merger of the two companies will mark a new beginning for the corporation, shifting away from modular home construction and into an integrated energy company with a strong container build business focusing on industrial builds such as generator sets, AI data centers and crypto currency miners,' McLaren noted."

To view the full article, visit https://ibn.fm/7Vg2E

Safe and Green Holdings Corp. (NASDAQ: SGBX) is a diversified holding company focused on delivering innovative solutions across infrastructure, construction, energy, healthcare, and environmental sectors. Originally established in 2007 as SG Blocks, the company has evolved into a vertically integrated platform serving both public and private sector clients with modular, sustainable systems. Its operations span a range of industries unified by a commitment to efficient, scalable design and sustainability-driven development.

The company’s model centers on the production and deployment of prefabricated modular structures, energy systems, and infrastructure technologies, leveraging vertical integration and cross-sector synergies to support government agencies, medical networks, developers, and commercial enterprises. Safe and Green’s subsidiaries operate collaboratively to generate multiple revenue streams while pursuing opportunities in both traditional and next-generation infrastructure.

Safe and Green Holdings Corp. is headquartered in Miami, Florida.

Portfolio

SG Echo Manufacturing

SG Echo is the modular manufacturing arm of Safe and Green Holdings Corp., delivering prefabricated structures built from steel, wood, and repurposed shipping containers. As a Made-in-America manufacturer, SG Echo combines industry-leading machinery and skilled labor to execute modular projects for clients across the U.S. and globally. The company holds an ESR certification from the International Code Council for repurposed containers, enabling faster approvals and widespread applicability in commercial and industrial construction.

With the ability to reduce construction time by up to 50% and cut costs by 10–20%, SG Echo’s manufacturing process emphasizes speed, sustainability, and resilience. In October 2025, SG Echo’s operations were consolidated into a new facility in Conroe, Texas, where they now operate alongside Olenox Corp., a Safe and Green subsidiary focused on oil and gas operations, to streamline logistics and integrate manufacturing with field operations. Revenue is also generated through third-party property leasing at the Conroe site.

SG Modular Medical

SG Modular Medical designs and deploys modular point-of-care solutions tailored for the evolving demands of healthcare infrastructure. The system enables clinics and labs to be rapidly assembled from clinical, administrative, and diagnostic modules, offering adaptability based on local needs and population shifts. This modular approach is positioned as a lower-emission alternative to traditional medical construction, helping reduce the substantial carbon footprint associated with healthcare infrastructure.

Notable deployments include COVID-19 testing pods at Los Angeles International Airport (LAX), designed and delivered in partnership with airport authorities. Another initiative, launched with The Peoples Healthcare and Teamsters Local 848, involves delivering modular clinics to serve union members with onsite, high-quality care staffed by a top-tier clinical operator.

SG Development Corp.

SG DevCorp is the real estate development division of Safe and Green Holdings Corp., focused on building modular single- and multifamily projects across various income levels. The company pursues strong, green developments supported by vertically integrated manufacturing from SG Echo. SG DevCorp has stated development targets of more than 4,000 modular units totaling over 3.2 million square feet across 1,000+ acres of acquired land—a construction pipeline valued at approximately $765 million.

The division prioritizes sustainability throughout the lifecycle of its developments, reducing construction waste, energy usage, emissions, and noise pollution. Its projects aim to minimize the environmental impact while enhancing speed-to-market and structural resilience.

SG Environmental Solutions

SG Environmental Solutions provides modular environmental infrastructure and sustainable waste management technologies. At the core of this division is Sanitec, a patented system designed for medical waste sterilization and volume reduction. The technology helps organizations reduce their environmental impact while significantly lowering operational costs.

The company emphasizes responsible construction and stewardship through upcycling, waste reduction, and adaptable modular deployments. Its container-based platforms are built for diverse use cases across commercial, residential, industrial, and environmental applications, with a focus on high-efficiency, reduced-emission outcomes.

Olenox Energy

Olenox Energy is the energy development arm of Safe and Green Holdings, focused on acquiring and revitalizing distressed oil and gas assets. In May 2025, the company acquired 1,600 acres of wells and leases from Sherman Oil & Gas and its affiliates, adding 111 wells to the Olenox portfolio. Since the acquisition, Olenox has produced over 3,000 barrels of oil and is currently achieving peak production rates of 55 barrels per day. The company is preparing additional workovers to add 25–30 bpd and has completed full asset mobilization into Texas. Olenox also holds a 51% stake in Winchester Oil & Gas, representing more than 500 wells across the state.

The company is executing its strategy to build a fully integrated oil and gas platform. Olenox operations remain in full compliance with the Texas Railroad Commission, with a stated emphasis on environmental stewardship and reduced lease operating expenses.

In September 2025, Safe and Green entered into an Open Collaborative Framework with OneQode, a global digital infrastructure company. The agreement supports joint development of spill detection, real-time telemetry, and command systems for remote energy assets, enhancing Olenox’s operational capabilities through automation and data infrastructure.

Market Opportunity

Safe and Green Holdings is positioned to capitalize on macro trends across multiple sectors. The construction and real estate industries continue to seek faster, greener alternatives to traditional building methods—needs that SG Echo and SG DevCorp address through prefabricated, modular designs. In healthcare, rising demand for scalable care infrastructure underscores the relevance of SG Modular Medical’s point-of-care solutions.

Within energy, Olenox targets long-term value in revitalizing overlooked oil and gas assets. Its operational model, combined with emerging infrastructure technology partnerships, aims to improve field performance while maintaining environmental compliance. Through this diversification, Safe and Green aligns its platform with infrastructure modernization, energy resilience, and sustainability imperatives.

Leadership Team

Michael McLaren, Chairman and Chief Executive Officer, brings over 30 years of leadership in the energy industry, including military and field service projects, mergers and acquisitions, and technology development. He is the founder of Olenox Ltd., a developer of proprietary energy systems, and holds advanced degrees in Science and Business from the University of British Columbia. McLaren has authored multiple papers on alternative fuels and energy systems and serves as a lead strategist for Safe and Green’s cross-sector growth.

Patricia Kaelin, CPA, Chief Financial Officer, has more than 30 years of experience in public company financial management, mergers and acquisitions, and strategic capital deployment. She previously served as CFO and CIO of a billion-dollar construction company overseeing operations across 14 states. Her background spans construction, healthcare, manufacturing, and real estate. Kaelin holds a bachelor’s degree in business administration with a concentration in accounting from California State University, Fullerton.

Jim Pendergast, Chief Operating Officer, has held executive leadership roles across multiple sectors, including energy, construction, and agriculture. He has served as COO, CFO, and CEO at public and private firms, overseeing operations, acquisitions, and project execution. He holds an MBA in international business and finance from McMaster University and a BA in political studies and economics from Queen’s University.

Safe and Green Holdings Corp. (NASDAQ: SGBX), closed Wednesday's trading session at $2.66, off by 5%, on 492,394 volume. The average volume for the last 3 months is 15,529,565 and the stock's 52-week low/high is $1.81/$122.88.

Recent News

• Safe and Green Holdings Corp. (NASDAQ: SGBX) - MissionIRNewsBreaks - Safe and Green Holdings Corp. (NASDAQ: SGBX) Nears Completion of Merger, Marking Shift to Integrated Energy Company
• NetworkNewsBreaks - Safe and Green Holdings Corp. (NASDAQ: SGBX) Sharpens Focus on Domestic Energy Development
• Safe & Green Holdings Corp. (NASDAQ: SGBX) Olenox Subsidiary Secures DOT Number as Service Division Prepares for Mobilization

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores, with results comparable to or exceeding those observed with the prior ointment formulation, supporting continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis.

To view the full press release, visit https://nnw.fm/9ngJA

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Wednesday's trading session at $1.23, off by 19.0789%, on 1,455,829 volume. The average volume for the last 3 months is 342,395 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - NetworkNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
• InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies
• US to End Mandatory Vaccination of Newborns Against Hepatitis B

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Wednesday's trading session at $2.28, up 8.5714%, on 1,090,384 volume. The average volume for the last 3 months is 508,274 and the stock's 52-week low/high is $1.4/$6.01.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
• InvestorNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
• NetworkNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2